Impact of in-Hospital Left Ventricular Ejection Fraction Recovery on Long-Term Outcomes in Patients Who Underwent Impella Support for HR PCI or Cardiogenic Shock: A Sub-Analysis from the IMP-IT Registry.
Impella
cardiogenic shock
left ventricle support
protect PCI
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
13 May 2023
13 May 2023
Historique:
received:
03
04
2023
revised:
03
05
2023
accepted:
10
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
(1) Background: Percutaneous left ventricle assist devices (pLVADs) demonstrated an improvement in mid-term clinical outcomes in selected patients with severely depressed left ventricular ejection fraction (LVEF) undergoing percutaneous coronary interventions. However, the prognostic impact of in-hospital LVEF recovery is unclear. Accordingly, the present sub-analysis aims to evaluate the impact of LVEF recovery in both cardiogenic shock (CS) and high-risk percutaneous coronary intervention (HR PCI) supported with pLVADs in the IMP-IT registry. (2) Methods: A total of 279 patients (116 patients in CS and 163 patients in HR PCI) treated with Impella 2.5 or CP in the IMP-IT registry were included in this analysis, after excluding those who died while in the hospital or with missing data on LVEF recovery. The primary study objective was a composite of all-cause death, rehospitalisation for heart failure, left ventricle assist device (LVAD) implantation, or heart transplantation (HT), overall referred to as the major adverse cardiac events (MACE) at 1 year. The study aimed to evaluate the impact of in-hospital LVEF recovery on the primary study objective in patients treated with Impella for HR PCI and CS, respectively. (3) Results: The mean in-hospital change in LVEF was 10 ± 1% (
Identifiants
pubmed: 37240996
pii: jpm13050826
doi: 10.3390/jpm13050826
pmc: PMC10222801
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Pers Med. 2023 Feb 06;13(2):
pubmed: 36836527
EuroIntervention. 2020 Feb 07;15(15):e1343-e1350
pubmed: 31422925
N Engl J Med. 2017 Dec 21;377(25):2419-2432
pubmed: 29083953
Eur Heart J Acute Cardiovasc Care. 2021 Dec 6;10(9):999-1006
pubmed: 34389852
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Catheter Cardiovasc Interv. 2021 Aug 1;98(2):E222-E234
pubmed: 33793051
Am Heart J. 2022 Jun;248:139-149
pubmed: 35192839
Int J Cardiol. 2022 Sep 1;362:47-54
pubmed: 35533755
Lancet. 2013 Nov 16;382(9905):1638-45
pubmed: 24011548
JACC Cardiovasc Interv. 2021 Mar 22;14(6):717-719
pubmed: 33736787
JAMA. 2010 Aug 25;304(8):867-74
pubmed: 20736470
J Am Coll Cardiol. 2015 Dec 15;66(23):2663-2674
pubmed: 26670067
Eur J Heart Fail. 2020 Feb;22(2):330-337
pubmed: 31863563
J Am Coll Cardiol. 2013 May 7;61(18):1860-70
pubmed: 23500234
Cardiovasc Revasc Med. 2022 Oct;43:104-111
pubmed: 35398008
Catheter Cardiovasc Interv. 2017 Aug 1;90(2):E46-E52
pubmed: 28029210
JACC Cardiovasc Interv. 2020 May 25;13(10):1171-1178
pubmed: 32360256
N Engl J Med. 2022 Oct 13;387(15):1351-1360
pubmed: 36027563
N Engl J Med. 2019 Aug 22;381(8):739-748
pubmed: 31433921
Circulation. 2012 Oct 2;126(14):1717-27
pubmed: 22935569
Circulation. 2019 Mar 5;139(10):1249-1258
pubmed: 30586755
Eur Heart J Acute Cardiovasc Care. 2021 Jun 30;10(5):570-583
pubmed: 34057173
J Invasive Cardiol. 2019 Sep;31(9):E265-E270
pubmed: 31478893
Cardiol J. 2016;23(4):374-83
pubmed: 27515481
J Pers Med. 2022 Sep 24;12(10):
pubmed: 36294715
N Engl J Med. 2022 Oct 13;387(15):1426-1427
pubmed: 36027562
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992